Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561093 · ClinicalTrials.gov registry record · Phase 3
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
A Phase 3 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT00561093 is a Phase 3 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 93 participants.
The verdict
NCT00561093, a Phase 3 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of malnutrition-inflammation-cachexia syndrome in maintenance hemodialysis patients
Interventions
- DRUG pentoxiphylline
- DIETARY_SUPPLEMENT Nepro
- DIETARY_SUPPLEMENT anti-inflammatory module (similar to Oxepa)
- DRUG Placebo pill imitating pentoxiphylline
- DIETARY_SUPPLEMENT Placebo to imitate Nepro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561093
The ClinicalTrials.gov registry entry for NCT00561093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pentoxiphylline is the first listed.
NCT00561093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561093 about?
NCT00561093 is a clinical study titled "Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients". Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of malnutrition-inflammation-cachexia syndrome in maintenance hemodialysis patients
What is the current status of trial NCT00561093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00561093?
The interventions under investigation include: pentoxiphylline (DRUG), Nepro (DIETARY_SUPPLEMENT), anti-inflammatory module (similar to Oxepa) (DIETARY_SUPPLEMENT), Placebo pill imitating pentoxiphylline (DRUG), Placebo to imitate Nepro (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00561093?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.